Phase 3 placebo-controlled study of itepekimab in former smokers with moderate to severe COPD

Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Itepekimab 300 mg every 2 weeks, Itepekimab 300 mg every 4 weeks alternating with placebo and Placebo every 2 weeks (3 arms). Primary endpoint: Efficacy, safety, and tolerability of itepekimab versus placebo over 52 weeks. Started Feb 2021; status: recruiting.